Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
The goal of this study is to understand how the protein CD81 affects myeloid leukemia (especially AML) and whether it can help predict patient outcomes or guide treatment.
The main question it aims to answer:
Is high CD81 expression in myeloid leukemia cells linked to more aggressive disease, poorer treatment response, or shorter survival in patients?
Participants:
* Newly diagnosed myeloid leukemia patients (primary focus on AML) * Bone marrow or blood samples will be collected during routine diagnostic procedures
Eligibility criteria
Qualifiers
1. Myeloid leukemia patients 2. Patients of both genders (Males and females) at any age 3. Cases are de novo (Not on treatment)
Disqualifiers
. Patients with other haematological neoplasms (ALL,CLL, plasma cell myeloma, etc)
Patients under any therapeutic intervention
Patients with current or previous other malignancies at time of diagnosis
Trial design
Treatments tested in this trial
- Not listed
Trial groups
66 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov